| DIOVAN |
Valsartan |
| Chemical Name |
N-Pentanoyl-N-[2’-(1H-tetrazol-5-yl)biphenyl-4ylmethyl]-L-valine |
| Chemical Structure |
 |
| Australian Patent |
AU-B2-644844 |
| Expiry Date |
19 November 2013 |
| Patent Assignee |
Novartis AG |
| Title |
Biphenylylaliphathylamino compounds, their use as antihypertensives, pharmaceutical compositions and processes for their manufacture |
| Abstract |
Aromatic amide derivatives of  formula and their salts are new. (Where R1 = aliphatic hydrocarbon optionally substituted with halogen or OH, or a cycloaliphatic or araliphatic hydrocarbon. X1 = CO, SO2, or OCO with the carbon linked to the N. X2 = aliphatic hydrocarbon (optionally substituted with OH, carboxy, NH2, guanidino, cycloaliphatic or aromatic hydrocarbon) or cycloaliphatic hydrocarbon, with a carbon of the aliphatic optionally bridged by a divalent aliphatic hydrocarbon. R2 = carboxy or its ester or amide derivative, NH2, substituted amino, formyl, acetal derivative of formyl, 1H-tetrazol-5-yl, pyridyl, OH, ether, SR, SOR, SO2R, alkanoyl, sulphamoyl, N-substituted sulphamoyl, PO2H2 or PO3H2. R = H or aliphatic hydrocarbon. X3 = hydrocarbon. R3 = carboxy, 5-tetrazolyl, SO3H, PO2H2, PO3H2 or haloalkylsulphamoyl.; Rings A and B are each optionally substd. 121 compounds are specifically claimed, including (S)-N-(1-carboxy -2-methyl)-prop-1-yl) -N-pentanoyl-N- (2′-(1H-tetrazol-5-yl) biphenyl-4-ylmethyl) amine. |
| Australian Register of Therapeutic Goods |
ARTG ID 123357 |
| Consumer Medicine Information |
DIOVAN (Valsartan) |
| Product Information |
DIOVAN (Valsartan) |
| ROTATEQ |
Rotavius |
| Chemical Name |
rotavirus vaccine, live, oral, pentavalent, MSD |
| Chemical Structure |
– |
| Australian Patent |
AU-B2-618973 |
| Expiry Date |
28 November 2013 |
| Patent Assignee |
The Wistar Institute of Anatomy and BiologyThe Children’s Hospital Foundation |
| Title |
Novel rotavirus reassortant vaccine |
| Abstract |
The present invention provides novel rotavirus reassortants, vaccines employing the novel reassortants and methods for their preparation and administration. The reassortant contains at least the gene encoding the vp3 neutralization antigen of bovine rotavirus of the WC3 strain and the gene encoding the vp7 neutralization antigen of a selected human rotavirus. |
| Australian Register of Therapeutic Goods |
ARTG ID 120245 |
| Consumer Medicine Information |
ROTATEQ |
| Product Information |
ROTATEQ |
| AZELASTINE HYDROCHLORIDE |
Azelastine Hydrochloride Nasal Spray Formulation |
| Chemical Name |
(RS)-4-[(4-chlorophenyl)methyl]-2- (1-methylazepan-4-yl)-phthalazin-1-one Hydrochloride |
| Chemical Structure |
 |
| Australian Patent |
AU-B2-613107 |
| Expiry Date |
11 November 2013 |
| Patent Assignee |
MEDA Pharma GmbH & Co. KG |
| Title |
Azelastine-containing medicaments for application in the nose and/or at the eye |
| Abstract |
A medicament for nasal application or for application to the eye and/or the nose which contains 0.0005 to 2% (weight/weight) of azelastine or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent and/or adjuvant. A medicament according to claim 1 characterized in that it is used for the treatment of allergy-related, or vasomotor or rhino virus-related colds or symptoms. |
| Australian Register of Therapeutic Goods |
ARTG ID 104853 |
| Consumer Medicine Information |
AZEP Nasal Spray |
| Product Information |
– |
For further information please contact Rodney Chiang-Cruise or Aaron McMillan at IP Organisers Pty Ltd
IP Organisers is an Australian company specialising in the provision of intellectual property support services to Australian and international companies, organisations and professional services firms.
|
